巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Infinity Pharmaceuticals

    INFI
    1.270
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Infinity Pharmaceuticals - 延遲價格・最後更新於 15/08 22:00
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    1.270
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    113.38
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.890 - 0.461
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Infinity Pharmaceuticals
    證券代碼
    INFI.US
    所屬板塊
    Biotechnology
    公司業務
    Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.
    發行量
    89155311
    公司總部
    1100 Massachusetts Avenue, Floor 4
    公司網址
    https://www.infi.com
    公司電郵
    irpr_info@infi.com
    公司電話
    +1 617 453-1000
    暫無內容

    關於

    Infinity Pharmaceuticals(INFI.US)所屬的行業板塊為Biotechnology。
    Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.
    詳細公司背景可參考: https://www.infi.com